| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,900 | 7,000 | 06.02. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.01. | SMAIO Reports 2025 Sales of €9.2m, Representing an Increase of +67% | 243 | Business Wire | U.S. sales rose by +138% to €7m, and by +160% to $7.9m (excluding currency effects).
Strong growth across North American centers that were already active in 2024 (+130%). 11 new... ► Artikel lesen | |
| 08.01. | SMAIO: 2026 Financial Calendar | 303 | Business Wire | Regulatory News:
SMAIO (Software, Machines and Adaptive Implants in Orthopaedics Euronext Growth Paris, ISIN: FR0014005I80 Ticker: ALSMA), a French-American player specialized in complex spine... ► Artikel lesen | |
| 06.01. | SMAIO Obtains €2.0m in Non-Dilutive Financing | 323 | Business Wire | €1.0m in the form of a 0% interest loan co-financed by the European Union, the Auvergne-Rhône-Alpes Region and Bpifrance, with a repayment deferral period of two and a half years €1.0m... ► Artikel lesen | |
| 19.12.25 | SMAIO Successfully Continues Its Think Tanks Focused on Promoting Its Innovative Solutions in the United States | 422 | Business Wire | New attendance record at the New York session, bringing together nearly 60 experts from the spine sector, including over 40 surgeons
Regulatory News:
SMAIO (Software, Machines and Adaptative... ► Artikel lesen | |
| 24.11.25 | SMAIO appoints Matthieu Ville as chief commercial officer | 8 | Investing.com | ||
| 24.11.25 | SMAIO Appoints Matthieu Ville as Chief Commercial Officer to Accelerate Commercialization and Strengthen Its Leadership in Spinal Realignment | 262 | Business Wire | Matthieu Ville brings over 15 years of experience in medical marketing in the United States.
Regulatory News:
SMAIO (Software, Machines and Adaptative Implants in Orthopaedics- Euronext Growth... ► Artikel lesen | |
| 03.11.25 | DALLAS - Dr. Tenner Guillaume joins SMAIO's US scientific advisory board | 4 | Investing.com | ||
| S.M.A.I.O SA Aktie jetzt für 0€ handeln | |||||
| 03.11.25 | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 232 | Business Wire | Appointment of Dr. Tenner Guillaume, Orthopaedic spine surgeon who specializes in spinal deformity at Gillette Children's Hospital (St. Paul, Minnesota). SMAIO's US scientific advisory board... ► Artikel lesen | |
| 22.10.25 | SMAIO Signs a New Distribution Agreement for Its Open Platform KEOPS-4ME With Orthofix in the U.S. | 417 | Business Wire | Orthofix is a global medical technology company focused on healing musculoskeletal pathologies The distribution arrangement is part of SMAIO's collaborative strategy aimed at deploying... ► Artikel lesen | |
| 17.10.25 | SMAIO H1 Sales Increase | 1 | RTTNews | ||
| 14.10.25 | SMAIO Announces Strong First-Half 2025 Results and Robust Growth in Business Activity in the Third Quarter of 2025 | 270 | Business Wire | Strong sales growth in H1 2025: +126% to €5.0 million
Increase in gross margin in H1 2025 to 85% vs. 64% in H1 2024
Significant improvement in EBITDA (+96%) reaching break-even (vs.... ► Artikel lesen | |
| 24.09.25 | SMAIO Signs the First Major Distribution Agreement for Its Open Platform KEOPS-4ME with Highridge Medical in the U.S. | 358 | Business Wire | Highridge Medical is one of the world's largest privately held spine companies The partnership represents a key milestone in further expanding SMAIO's business activity in the U.S. and driving... ► Artikel lesen | |
| 16.07.25 | SMAIO Announces Significant Sales Increase in H1 2025 | 361 | Business Wire | Sales H1 2025: +126% to €5 million Acceleration of business activity in the United States (+360% to €3.8 million):
H1 2025 sales1 higher than full-year 2024 sales
More than... ► Artikel lesen | |
| 12.05.25 | SMAIO Announces the Finalization of a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 415 | Business Wire | The transaction was fully subscribed by NextStage AM, in accordance with the terms previously communicated
Regulatory News:
This press release may not be published, distributed or disseminated... ► Artikel lesen | |
| 15.04.25 | SMAIO Announces a €2.5 Million Fund-Raising, Consisting of a €1.5 Million Capital Increase and a €1 Million Convertible Bond Issue | 592 | Business Wire | Regulatory News:
This press release may not be published, distributed or disseminated, directly or indirectly, in the United States of America or Canada, Australia, Japan or South Africa.
SMAIO... ► Artikel lesen | |
| 15.04.25 | SMAIO Announces Consolidated Results for 2024 and Record Sales Performance in Q1 2025 | 570 | Business Wire | Sharp increase in sales, up +114%1 to €5.5 million in 2024 and +140% to €2.5 million in Q1 2025
Improvement in the margin rate on implant sales to 79% in 2024, vs. 71% at the end of 2023... ► Artikel lesen | |
| 28.02.25 | SMAIO Adds a New High-Profile Member to Its Scientific Advisory Board in the United States | 537 | Business Wire | Appointment of Dr. Donald J. Blaskiewicz, neurosurgeon at St. Luke's Clinic in Boise (Idaho) SMAIO's U.S. scientific advisory board now includes three North American surgeons, and is set... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | HV-Termine: Hauptversammlungen bei Adv. Blockchain, Aurubis, Fortec, Schott, Siemens, Healthineers, Stabilus, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PRIVIA HEALTH GROUP | 21,990 | +2,23 % | Privia Health Group, Inc.: Privia Health Reports Third Quarter 2025 Financial Results | Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q'24Implemented Providers +13.1% and Practice Collections +27.1%... ► Artikel lesen | |
| GERRESHEIMER | 25,660 | +1,99 % | JEFFERIES stuft GERRESHEIMER AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Gerresheimer mit einem Kursziel von 34,10 Euro auf "Buy" belassen. Analyst James Vane-Tempest zählt den Spezialverpackungshersteller... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 21,750 | +2,84 % | 6 Analysts Have This To Say About Alignment Healthcare | ||
| PROGYNY | 21,960 | +0,18 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| HIMS & HERS HEALTH | 19,500 | +0,15 % | Hims & Hers-Aktie -10%: Warum profitiert sie nicht? | Die Hims & Hers-Aktie schoss am gestrigen Donnerstag kurzfristig um über +10% in die Höhe, beendete den Handelstag dann aber doch mit einem Minus von fast -4%. Am Freitagmorgen bricht der Kurs der Gesundheitsplattform... ► Artikel lesen | |
| UNITEDHEALTH | 232,15 | -0,77 % | UnitedHealth: Das sieht gar nicht gut aus | Der enttäuschende Ausblick, den UnitedHealth dem Kapitalmarkt vor Kurzem an die Hand gegeben hat, und maue Aussichten für 2027 hinterlassen weitere Spuren im Aktienkurs des größten US-Krankenversicherers.... ► Artikel lesen | |
| RXSIGHT | 8,390 | +7,29 % | RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer |
ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen |